Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide plus Aromatase Inhibitor in Metastatic Breast Cancer
NCT02910050Phase 2Unknown
- Start
- Jan 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bicalutamide in breast cancer. Primary endpoint: Clinical Benefit Rate at 24 weeks. Status: unknown.
02
Drugs
bicalutamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02910050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910050.